Navigation Links
Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Date:10/26/2009

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the third quarter and first nine months of fiscal 2009 on Thursday, November 5.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m., Eastern Standard Time), Thursday, November 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 457-2658, passcode 2641790. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at www.volcanocorp.com.

A replay of the conference call will be available through Thursday, November 12, at (719) 457-0820, passcode 2641790, and via the company's website.

About Volcano Corporation

Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH® IVUS tissue characterization and ChromaFlo®. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) and Forward-Looking IVUS systems and catheters. Currently, more than 4,400 Volcano IVUS and FM systems are installed worldwide, and approximately half of Volcano's revenues are derived from outside the United States. Through its wholly-owned subsidiary, Axsun Technologies, Volcano also develops and manufactures optical monitors, lasers and optical engines used in telecommunications, spectroscopy and other industrial applications. These products are sold to a variety of customers, including Nokia Siemens, Ericsson, Alcatel-Lucent and HuaWei Technologies. For more information, visit the company's website at http://www.volcanocorp.com.

SOURCE Volcano Corporation


'/>"/>
SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
2. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
3. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
4. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
5. Select Medical Holdings Corporation Announces Exercise of Underwriters Option to Purchase Additional Shares
6. Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference
7. Mirixa Corporation Announces MirixaEdge(SM)
8. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
9. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
10. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
11. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and their ...
(Date:2/23/2017)... 23. Februar 2017 LG Innotek hat heute ... Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... Bereich zwischen 200 und 280 nm und eignet sich damit ... es ihre DNA zerstört. Das Produkt von LG Innotek ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure ... a specific LRRK2 mutation, according to a study released today at the 1st ... of a link between pesticides and incidence of sporadic PD through occupational exposure. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... 24, 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s ... of his paramedic experiences. Schanssema describes the tragedies he saw, as well as his ... them. , Schanssema, initially unsure of the career path he wanted to take, found ...
Breaking Medicine News(10 mins):